Pharma giant spends 26 million dollars in US lobbying for obesity drug

Denmark’s biggest company, Novo Nordisk, has spent at least DKK177m ($25.8) over the past decade on a massive lobbying effort in the U.S. to encourage doctors and health professionals to promote its anti-obesity medications Wegovy and Saxenda. News Agency Reuters reports how the global phamaceutical giant, primarily known for diabetes medicines, is transforming itself into the world’s biggest weight-loss company, targeting 764 million people with obesity across the globe. In…